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Abstract
Lysine-specific demethylase 1 (LSD1) is frequently elevated in acute myeloid leukemia 
(AML) and often leads to tumorigenesis. In recent years, numerous LSD1 inhibitors 
based on tranylcypromine (TCP) scaffolding have reached clinical trials. Most TCP 
derivatives were modified at the amino site of cyclopropane motif. Herein, we for the 
first time introduced a sulfonamide group in TCP benzene ring of series a compounds 
and performed a systematical study on structure and activity relationships by varying 
sulfonamide groups. The introduction of sulfonamide significantly increased the 
targeting capacity of TCP against LSD1. Moreover, we discovered that the Boc attached 
LSD1 inhibitors (labelled as series b compounds) substantially improved their anti-
proliferation capacity towards AML cells. The intracellular thermal shift and LC-
MS/MS results implied that Boc enhanced the drug lipophilicity and might be removed 
under the cancerous acidic environment to release the real pharmacophore, evidenced 
by the fact that a structurally similar but acidic inert pivaloyl to replace Boc 
dramatically dropped the cellular anti-proliferation effect. Finally, a benzyl group 
installed at the amino site to appropriately increase lipophilicity led to trans-4-(2-
(benzylamino)-cyclopropyl)-N,N-diethylbenzenesulfonamide a10 that showed better 
anti-proliferation activity in AML cells and enzymatic inhibition against LSD1. Taken 
together, our work offers a novel TCP-based structure and provides a prodrug strategy 
for the discovery of potent LSD1 inhibitors by having appropriate lipophilicity.




Aberrant epigenetic modification is a hallmark of hematological malignancy and 
correlated with the leukemic transformation.[1, 2] Simultaneously, epigenetic 
regulation is a highly dynamic process manipulated by multiple enzymes, and such 
process can be used as a potential drug target.[3-6] An epigenetic modification enzyme, 
lysine-specific demethylase 1 (LSD1, also known as KDM1A), is a nuclear amine 
oxidase homolog and specifically targets mono- and di-methylated lysine 4 and lysine 
9 of histone H3 (H3K4me1/2, H3K9me1/2) using flavin adenine dinucleotide (FAD) 
as the coenzyme.[7-11] Evidences suggest that LSD1 is often elevated in acute myeloid 
leukemia (AML), particularly poor-differentiated AML harboring chromosomal 
translocation.[12] A combination of LSD1 inhibitors with all-trans-retinoic acid 
(ATRA) has been used to break the differentiation blockade in AML.[13] Therefore, 
LSD1 is emerging as an essential target for AML therapy.
In the past decades, numerous LSD1 inhibitors were developed and could be divided 
into irreversible and reversible types according to their action mechanisms.[14-25] 
Currently, irreversible LSD1 inhibitors based on tranylcypromine (TCP) scaffolding 
have achieved good progress, illustrated by the two most advanced drug candidates 
ORY-1001 and GSK2879552 (Figure 1A).[26, 27] Their inhibition mechanism 
involves the formation of an amine cation radical to covalently react with FAD to block 
the biological function of LSD1 (Figure 1B). As far as we know, ORY-1001 and 
GSK2879552 have entered into phase Ⅰ clinal trials with enzymatic inhibition at a 
nanomolar level (Figure 1C). The development of irreversible LSD1 inhibitors often 
focuses on the alteration of the cyclopropane amino side, and there are relatively few 
reports of modifications on the benzene ring.[28-31] The sulfonamide group is 
frequently employed in the drug development [32] and it is shaped in a tetrahedron 
three-dimension, very different from the planar amides.[33] Thus, it was of our interest 
to install a sulfonamide on the benzene ring of TCP to develop novel potent LSD1 
inhibitors.
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Figure 1. (A) The structures, (B) inhibitory mechanism and (C) enzymatic activities of 
three representative irreversible LSD1 inhibitors based on TCP scaffolding.
2. Results and discussion
2.1. Chemistry
Numerous LSD1 inhibitors were often modified at the cyclopropane amino side. 
Structure-activity relationship studies (SARs) on the benzene ring were relatively scant, 
for example, a reported LSD1 inhibitor T-3775440 has a para-positioned 
carboxamide.[34] For the first time, we introduced the sulfonamide group at the 
benzene ring side of TCP to develop novel LSD1 inhibitors (Figure 2). As a result, a 
series of compounds defined as series a was designed. Simultaneously, in our previous 
work, compounds with Boc group contributed to an increased cellular uptake, and it 
was of our interest to further explore its advantage. Thus, Boc group was newly 
introduced at the cyclopropane amino side to obtain series b compounds. Meanwhile, 
c9 with a structurally similar pivaloyl was also designed.
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Figure 2. The racemic compounds designed from tranylcypromine. (A) Series a 
compounds with a free amine. (B) Series b compounds with Boc at the cyclopropane 
amino site. (C) Series c compound with a pivaloyl.
All the racemic compounds a1-a10, b1-b10 and c9 were synthesized via the routes 
described in Scheme 1. Commercially available 2-phenyloxirane (labeled as 1) was 
reacted with triethyl phosphonoacetate in the presence of n-BuLi to acquire trans-
cyclopropyl ester 2.[33] Following a procedure of Huntress’ work,[35] 2 was treated 
with chlorosulfonic acid in anhydrous dichloromethane, and a chlorosulfonyl group was 
successfully installed in the para position of the benzene ring to afford compound 3. 
Then, a series of different amino groups were added respectively to get 4 with varying 
sulfonamides. Series b compounds b1-b9 were then obtained after three steps. Firstly, 
4 were hydrolyzed into acids 5 under subjection to LiOH, and the following coupling 
reaction with DPPA at room temperature provided acyl azide 6. Curtius rearrangement 
in the refluxing t-BuOH resulted in the formation of compounds b1-b9. Meanwhile, 
deprotection of Boc using HCl in methanol gave series a compounds a1-a9 in a 
hydrochloride salt form (Scheme 1A). For the preparation of c9, compound a9 reacted 
with pivaloyl chloride in presence of DIPEA to assemble c9 (Scheme 1B). Additionally, 
compound b10 was also synthesized from b9 by introducing a benzyl group (Scheme 
1C), and the Boc deprotection from b10 afforded compound a10. As a result, both alkyl 
and aryl primary amines as well as both cyclic and acyclic secondary amines were 
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installed to construct three series of novel sulfonamide TCP derivatives for further 
anticancer screening.
Scheme 1. Synthesis of the designed compounds. Reagents and conditions: (a) triethyl 
phosphonoacetate, n-BuLi, 1,4-dioxane, r.t., then microwave at 135 oC for 60 min; (b) 
chlorosulfonic acid, anhydrous CH2Cl2, 0 oC-r.t., 3 h; (c) DIPEA, anhydrous CH2Cl2, 0 
oC-r.t., 2 h; (d) THF/H2O (3:1), LiOH, r.t., 3 h; (e) Et3N, DPPA, THF, r.t., 4 h; (f) t-
BuOH, reflux, 12 h; (g) HCl/MeOH, r.t., 2 h; (h) DIPEA, anhydrous CH2Cl2, r.t., 2 h; 
(i) NaH, benzyl bromide, THF, r.t., 2 h. Note: the compounds are racemic.
2.2. Preliminary anti-proliferation screening of modified TCP derivatives at the 
cellular level
The selection of appropriate cancer cell lines to evaluate the anti-proliferation effect 
of inhibitors is essential for acquiring realistic results. Several reports have studied drug 
sensitivity to LSD1 inhibitors in numerous cell lines of hematopoietic malignancy, and 
acute myeloid leukemia MV4-11 was regarded as the drug-sensitive cell line towards 
LSD1 inhibition.[36, 37] Before the preliminary screening of our synthetic compounds, 
we wanted to confirm the reported results firstly. LSD1 was significantly elevated in 
acute myeloid leukemia via analyzing patient-derived data from the Oncomine database 
(Figure S1A). After ORY-1001 and GSK2879552 were confirmed to inhibit LSD1 at 
nanomolar concentrations (Figure 1C), these two compounds and TCP were employed 
to screen AML cell lines treated with each drug at 5 μM for 8 days. Among six tested 
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AML cell lines, MV4-11 was found to be most sensitive towards LSD1 inhibition, 
which was consistent with literature reports (Figure 3A and Figure S1B-F).[36] 
Although both ORY-1001 and GSK2879552 quickly reached 40 % inhibition of cancer 
cell growth at low concentrations (< 1 μM), they could not inhibit cell growth further 
at higher concentrations (Figure 3B). The results suggested that the development of 
more potent LSD1 inhibitors to increase their cellular anti-proliferation capacity would 
be highly favorable.
Compounds a1-a9 and b1-b9 were screened for their anti-proliferation capacity 
using MV4-11 cell line at three gradient concentrations (1 μM, 10 μM and 30 μM) via 
MTS assay, as shown in Figure 3C-E. At a low concentration of 1 μM, most of the 
synthetic compounds did not prevent cancerous cell growth obviously. While the 
dosage increased (10 μM and 30 μM), some compounds especially b9 started to show 
substantial anti-proliferation capacity, which was significantly better than the three 
typical positive compounds (TCP, ORY-1001 and GSK2879552). Series b compounds 
with Boc group exhibited better anti-proliferation activity than the corresponding series 
a compounds with only free amines at 10 μM and 30 μM (Figure 3F).
Compared to the simple TCP, the lipophilic alkylsulfonamides seemingly increased 
the anti-proliferation potency of many of series b compounds. Notably, the best 
compound b9 almost fully inhibited the cell growth of MV4-11, much better than three 
well-known LSD1 inhibitors. CLogP is a classic parameter representing lipid solubility, 
and its range between 1 to 5 is optimal for the drug development. To study the potential 
relationship between lipophilicity and anti-proliferation capacity of the synthetic 
compounds, CLogP values were calculated by ChemDraw and the correlation analysis 
was conducted through GraphPad Prism. Series a compounds exhibited a lower CLogP 
value (< 2.4), likely leading to the worse cellular uptake. Consequently, the cell growth 
inhibitory rate of a1-a9 at 30 μM were below 50 % (Table S1). Introduction of Boc 
group improved the lipophilicity of compounds b1-b9, and the inhibition rates were 
elevated as a result. Especially, while the ClogP reached the range of between 3.0 and 
4.0, the anti-proliferation capacity of compounds was enhanced significantly. 
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Collectively, there was an apparent positive correlation between cell inhibition at 30 
μM dosage and lipophilicity as shown in Figure 3G, implying that series b compounds 
might increase their cellular anti-proliferation capacity via an elevated lipophilicity 
mediated by the Boc group.
Figure 3. Primary cellular anti-proliferation screening of our synthetic compounds. (A) 
Cell counting after treatment with three typical TCP-derived LSD1 inhibitors at 5 μM 
for 8 days. (B) Cell viability after treatment with three inhibitors at gradient dosages for 
6 days, determined by MTS assay. (C-E) Preliminary anti-proliferation effect screening 
of TCP derivatives in MV4-11 cell line via MTS assay at three gradient concentrations, 
(C) 1 μM, (D) 10 μM and (E) 30 μM. (F) Quantitative anti-proliferation comparison of 
three known inhibitors, series a and series b compounds. (G) Correlation analysis of 
anti-proliferation capacity at 30 μM against CLogP values. All data are representative 
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of 3 independent experiments and shown as mean ± SD of triplicates. n.s. no 
significance, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by unpaired, 2-tailed 
Student’s t test.
2.3. Comparison between series a and b compounds at the enzymatic level
Following the preliminary cellular anti-proliferation screening results, we further 
look at the enzymatic inhibition activity of these two series compounds. Targeting 
ability against LSD1 was determined by a commercially available LSD1 Inhibitor 
Screening Assay Kit (#700120, Cayman Chemical, USA), and IC50 values in the 
enzymatic inhibition level were presented in Table 1. Enzymatic curves were shown in 
Figure S2A-L. All series a compounds were better than the parent inhibitor TCP (IC50, 
22 μM) with their IC50 values at nanomolar levels, indicating that the introduction of 
sulfonamide groups significantly enhanced their LSD1 targeting ability. Surprisingly, 
no significant LSD1 inhibition was observed in all series b compounds at 1000 nM 
(Figure S2M), which was counterintuitive. It seemed that other factors including 
lipophilicity might play a crucial effect on the ani-proliferation capacity of series b 
compounds.
Table 1. Enzymatic inhibitory activity of the synthetic compounds (IC50).
Series a  IC50 (μM) Series b     IC50 (μM)
a1 0.3691 b1     > 1
a2 0.2006 b2     > 1
a3 0.4927 b3     > 1
a4 0.4973 b4     > 1
a5 0.2922 b5     > 1
a6 0.8413 b6     > 1
a7 0.1994 b7     > 1
a8 0.2382 b8     > 1
a9 0.1229 b9     > 1
The IC50 value indicated the concentration that achieved half inhibition of enzymatic activity.
2.4. The Boc in series b compounds served as a prodrug functional group
Due to the potential lability of Boc to acids, we hypothesized that Boc might be 
removed within cancerous acid environment to release the real LSD1 inhibitors from 
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series b compounds that did not show detectable inhibition on recombinant LSD1 as 
shown in Table 1. Therefore, the intracellular LSD1 targeting ability was further tested 
via thermal shift experiments within cells that were pretreated with each compound. 
The results, as shown in Figure 4A, indicated that both a9 and b9 could stabilize LSD1 
protein almost to the same level, confirming that series b compounds were able to target 
cellular LSD1. The action mechanism of TCP compounds to inhibit LSD1 is associated 
with the generation of amino cation radicals to covalently form an adduct with FAD 
(Figure 1B).[26, 27] The Boc at the amino site might decrease the nitrogen 
electronegativity to prevent a cation radical from formation, which was the reason why 
b9 did not show apparent enzymatic inhibition of recombinant LSD1. Meanwhile, these 
results might support our hypothesis that Boc in b9 might be removed intracellularly to 
generate the free amine a9 to act as a real LSD1 inhibitor. To further validate our 
hypothesis, the Boc in b9 was changed to a structurally similar pivaloyl group that is 
not easily removed even under strong acid environment. Thus, compound c9 was 
designed and synthesized as shown in Scheme 1B. Cellular thermal shift experiments 
showed that c9 did not stabilize LSD1 significantly and moreover its cellular anti-
proliferation effect dropped dramatically (Figure 4B and 4C). Meanwhile, c9 did not 
inhibit the enzymatic activity of LSD1 in vitro (Figure S3A). Based on these findings, 
the Boc might serve as a prodrug functional group in TCP derivatives to increase cell 
permeability and achieve a more effective anti-proliferation effect.
Furthermore, LC-MS/MS was used to investigate the potential intracellular 
conversion of b9 to a9 into a real LSD1 inhibitor. Firstly, such conversion was tested 
in the culture medium without cells in vitro (Figure S3B). The mass ion signal of a9 
could be detected at pH 6.5 and it substantially increased at pH 6, indicating a 
possibility that series b compounds were able to convert to series a compounds under 
such weak acid conditions. To further validate the in vitro results, MV4-11 cells were 
treated with 10 μM of either a9, b9 or c9 for 3 days and 6 days, and then the cells were 
lysed and extracted using a solvent system (chloroform : methanol : water = 6 : 3 : 1). 
The extract was dried via nitrogen blower concentrator and then re-dissolved in 50 % 
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MeOH/H2O solution for further LC-MS/MS analysis. The data as shown in Figure 4D 
and 4E, clearly demonstrated that a9 could be detected in both samples treated with a9 
and b9. The signal of a9 detected in b9-treated cell samples was significantly higher 
than in a9-treated cell samples. Moreover, cellular concentration of a9 converted from 
b9 steadily sustained high while the a9-treated samples contained less a9 after 6 days, 
likely resulting from the continuous consumption of a9 by covalently binding to LSD1 
co-enzyme FAD as shown in Figure 1B. Meanwhile, a9 was rarely detected in the c9-
treated samples as expected. Taken together, the continuous and steady supply of 
cellular a9 from b9 might contribute to its better anti-proliferation capacity, 
demonstrating the potential of Boc as a prodrug group (Figure 4F).
Figure 4. The intracellular LSD1 targeting capacity of series b compounds with the 
Boc group. (A-B) Cellular thermal shift assay of LSD1 in MV4-11 cells treated for 24 
h with (A) a9, b9 and (B) c9 at 5 μM. The level of LSD1 was determined by Western 
blot. (C) Dose-response curves for the cell viability of MV4-11 cells treated with each 
drug for 6 days, determined by MTS assay. (D-E) LC-MS/MS detection of a9 in MV4-
11 cells treated with each drug at 10 μM for (D) 3 days and (E) 6 days. (F) Potential 
conversion mode from b9 to a9 within cancerous acid environment. All data are 
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representative of 3 independent experiments and shown as mean ± SD. **p < 0.01, ***p 
< 0.001, ****p < 0.0001 by One-way ANOVA, Dunnett test.
2.5. Compounds a9 and b9 promoted myeloid differentiation
Many examples in the literatures demonstrated that the anticancer effect of LSD1 
inhibitors is often involved in the induction of cell differentiation in AML.[26] Since 
CD11b is regarded as a myeloid differentiation marker, we detected the level of CD11b 
to compare the effect of compounds a9, b9 and c9. The treatment with each of these 
three compounds for 24 h did not show any impact on MV4-11 cells. However, after 
96 hour treatment, both a9 and b9 significantly induced myeloid differentiation while 
c9 did not (Figure 5A-C). Meanwhile, compound b9 induced more differentiation than 
a9, which might result in the better anti-proliferation activity of series b compounds. 
Similar results were also validated in another AML cell line, HL-60 (Figure 5D-F).
Figure 5. Compounds a9 and b9 induced myeloid differentiation. (A, B) Flow 
cytometry analysis of CD11b on MV4-11 cells treated for (A) 24 h and (B) 96 h with 
each drug at 10 μM. (C) Statistic quantitative analysis of the mean CD11b fluorescence 
intensity from Figure 5A and 5B. (D, E) Flow cytometry analysis of CD11b of HL-60 
cells treated for (D) 24 h and (E) 96 h with each drug at 10 μM. (F) Statistic quantitative 
analysis of the mean CD11b fluorescence intensity from Figure 5D and 5E. All data are 
representative of 3 independent experiments and shown as mean ± SD. n.s. no 
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significance, ***p < 0.001, ****p < 0.0001 by unpaired, 2-tailed Student’s t test.
2.6. Further lipophilic benzyl installation led to a10 with potent LSD1 inhibition 
and improved anticancer capacity
Based on our observation, appropriate lipophilicity was crucial for TCP-based LSD1 
inhibitors to enter cancer cells to enact their intracellular biological function. Compared 
with series a compounds, series b compounds with a Boc had a properly high CLogP 
values and displayed better anticancer capacity, likely due to their improved 
intracellular uptake. Therefore, a lipophilic functional group could be installed at the 
amino site to increase lipophilicity while remaining enzymatic LSD1 inhibitory 
potency. Thus, compound a9 with the best enzymatic LSD1 inhibition was selected to 
install a benzyl group at the cyclopropane amino site, leading to a new compound a10 
with an elevated CLogP. The introduction of the lipophilic benzyl group surprisingly 
improved the cell growth inhibition and LSD1 targeting capacity (Table 2 and Figure 
S4). Notably, a10 showed better selectivity against LSD1 over other homologous 
enzymes MAO-A and MAO-B. Meanwhile, the cellular anti-proliferation capacity of 
b10 dropped compared to the parental compound b9, implying that too high 
lipophilicity (CLogP > 5) might impair cell permeability of b10 although b10 was able 
to bind to cellular LSD1 as demonstrated in the cellular thermal shift experiment (Table 
S2 and Figure S5A). Since a10 showed the best potency against recombinant LSD1 
although it inhibited MV4-11 at a slightly higher IC50 concentration compared to b10 
(Figure S5B), a10 was chosen for further biological studies. Cell counting experiments 
confirmed that a10 significantly blocked cell growth at 5 μM after 6 days of treatment 
(Figure S5C). Moreover, two other AML cell lines Kasumi-1 and BaF3/ITD also 
displayed good anti-proliferation responses to the treatment of a10 (Figure S5D). The 
direct outcome of LSD1 inhibition was an elevation of H3K4 and H3K9 methylation 
levels. Indeed, our experiment confirmed that the degrees of H3K4me1, H3K4me2 and 
H3K9me2 increased significantly after a treatment with a10, especially at 10 μM 
(Figure 6A and 6B). Thermal shift experiment also verified that a10 could bind to 
cellular LSD1 to prevent its thermal destabilization (Figure 6C).
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Cell Growth LSD1 MAO-A MAO-B CLogP
TCP > 30 22a 0.2691 0.5067 1.5
a9 > 30 0.1229 0.8067 0.8975 1.7
a10 15.4 0.0290 0.5255 0.7017 3.9
The IC50 value indicated the concentration that achieved half inhibition of either cell growth or enzymatic 
activity. CLogP values were analyzed via ChemDraw. a Reported in the commercial LSD1 Inhibitor 
Screening Assay Kit.
Since a10 inhibited LSD1 both extracellularly and intracellularly, the consequent 
effect on cell cycle and cell differentiation was tested. After 24 hour treatment, a10 
blocked the cell cycle at G0/G1 phase along with the proportional decrease at S and 
G2/M phase (Figure 6D). Three reported LSD1 inhibitors required longer time to cause 
a substantial cell cycle arrest (Figure S5E), whereas a10 already caused more AML 
cells death. CD11b, a marker of myeloid differentiation, was also examined. The four 
compounds did not exhibit an obvious impact on CD11b expression in MV4-11 cells 
treated for a short 24 h time. However, after 96 hour treatment, a10 substantially 
increased the level of CD11b, better than the other three known LSD1 inhibitors (Figure 
6E). The induction of myeloid differentiation was also validated in HL60 cell line 
(Figure S5F). Taken together, compound a10 targeted LSD1 and subsequently 
prevented cell growth via cell cycle blockade and myeloid differentiation promotion.
The combination of two drugs is often employed to increase their pharmacological 
efficacy.[38, 39] Examples in the literature have demonstrated that LSD1 inhibitors in 
a combination with the clinical drug ATRA exhibited better anticancer effects.[13, 37] 
Our synthetic compound a10 was further investigated in a co-treatment with ATRA, 
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and indeed such a combination achieved a synergistic anti-proliferation effect towards 
MV4-11 cells via MTS assay (Figure 6F，6G and Figure S5G).
Figure 6. Compound a10 caused cell cycle blockade, induced myeloid differentiation 
and exhibited a synergistic effect with the clinical drug ATRA in MV4-11 cell line. (A) 
Western blot of LSD1 methylated markers treated with a10 at various concentrations 
for 24 h. (B) Statistical analysis of the methylation levels in A (Student’s t test, 
unpaired, 2-tailed). (C) Thermal shift assay of intracellular LSD1 with a10 at 5 μM for 
24 h. (D) Flow cytometry analysis of cell cycle after 24 hours treatment with each drug 
at 10 μM (One-way ANOVA, Dunnett test). (E) Flow cytometry analysis of CD11b 
after treatment with each drug at 10 μM for 24 h and 96 h (One-way ANOVA, Dunnett 
test). (F) Dose-response curves of cells co-treated with a10 at various concentrations 
and ATRA at indicated concentrations for 6 days. (G) Combination index (CI) of 
combinations of a10 and ATRA, analyzed by Calcusyn Software. CI less than 1 means 
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a synergistic effect. All data are representative of 3 independent experiments and shown 
as mean ± SD. n.s. no significance, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
3. Conclusions
In our present work, a new series of TCP-based LSD1 inhibitors were developed and 
evaluated against AML. The introduction of sulfonamide groups in TCP benzene ring 
site substantially increased the LSD1 inhibition potency. Meanwhile, our work 
demonstrated that an appropriate lipophilicity and potent LSD1 inhibition contributed 
to the improved anti-proliferation effect of LSD1 inhibitors towards AML cell lines. 
The lipophilic Boc group installed in the polar TCP derivatives benefited the drug 
cellular uptake and could be removed to release the real LSD1 inhibitors under acidic 
microenvironment in cancer cells. Cellular protein thermal shift experiments further 
verified that the best anticancer Boc-attached TCP derivative b9 stabilized intracellular 
LSD1 although it did not inhibit the recombinant enzyme. Moreover, the mass 
spectroscopy further confirmed the intracellular release of the real LSD1 inhibitor a9 
from b9. Finally, a novel compound a10 bearing an appropriate lipophilicity was 
developed, and it substantially inhibited LSD1 and exhibited a good anticancer capacity 
in several AML cell lines. a10 may provide a new structural scaffolding to develop 




Reagents and solvents were commercially available and used without further 
purification. All nuclear magnetic resonance (NMR) spectra, including 1H NMR and 
13C NMR spectra, were recorded on a Bruker Avance 400 MHz and 100 MHz 
spectrometer with TMS as an internal standard. Chemical shifts were exhibited in parts 
per million (δ, ppm) and referenced to CDCl3 with 7.26 for 1H and 77.16 for 13C, and 
to methanol-d4 with 3.31 for 1H and 49.00 for 13C. High-resolution mass spectra (HRMS) 
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were recorded on a Shimadzu Micromass Q-T of Micromass spectrometer by 
electrospray ionization (ESI). Agilent 1100 HPLC system equipped with an Eclipse 
XDB-C18 column was used to determine the purity of all final compounds. The flow 
rate of HPLC was set at 1 mL/min and the gradient elution was run for 15 min, from 10 
% MeOH/H2O to 90 % MeOH/H2O for 8 min and 90 % MeOH/H2O for another 7 min. 
In addition, 1 ‰ formic acid was added to the methanol to elevate the solubility of free 
amine compounds.
4.1.2. The procedures for synthesis of series a and b compounds
The appropriate triethyl phosphonoacetate (4.11 g, 1.1 equiv) was dissolved in 8 mL 
of anhydrous 1,4-dioxane (8 mL), and then n-BuLi (1.23 g, 1.2 equiv) was added at 0 
oC carefully. After stirring for 30 min, 2-phenyloxirane (2.0 g, 1.0 equiv) was added, 
and then the reaction mixture was subjected to microwave at 135 oC for 1 h. The 
reaction was stopped using aqueous saturated NH4Cl, and the mixture was extracted 
with EtOAc. The organic phases were washed with brine, dried over Na2SO4 and finally 
purified with column chromatography (PE/EtOAc = 50:1) to obtain 2 as a red oil (2.87 
g, 91 % yield). Then chlorosulfonic acid (12.5 equiv) was dissolved in anhydrous 
CH2Cl2 (20 mL), and then 2 (2.87 g, 1.0 equiv) in anhydrous CH2Cl2 (5 mL) was 
dropped into the mixture over a period of 1 h at 0 oC. The reaction continued for another 
2 h at room temperature. The mixture was finally extracted with CH2Cl2 three times 
and purified via column chromatography (PE/EtOAc = 5:1) to obtain 3 as a yellow oil 
(2.79 g, 64 % yield). Then a series of amines were introduced at the sulfonyl group side 
and all compounds shared the following general synthetic procedure.
Compound 3 (1.0 equiv) was sufficiently dissolved in anhydrous CH2Cl2, then each 
type of amine (1.2 equiv) and DIPEA (2.0 equiv) was added at 0 oC respectively. The 
reaction was stirred at room temperature for 2 h to obtain 4. Compound 4 (1.0 equiv) 
was dissolved in THF/H2O (3:1) and then LiOH (2.0 equiv) was added. The reaction 
continued for 12 h at room temperature to get 5. DPPA (1.2 equiv) and Et3N (1.2 equiv) 
were added dropwise at 0 oC into the solution of 5 (1.0 equiv) in anhydrous THF. The 
reaction mixture was stirred for 2.5 h at room temperature, and extracted with EtOAc 
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and purified with column chromatography to get 6. The solution of 6 (1.0 equiv) in t-
BuOH was refluxed at 110 oC for 12 h to finally obtain series b compounds b1-b9.
Deprotection of Boc group under an acidic condition gave compounds a1-a9. Series 
b compound was weighed into the bottle, and a HCl solution in methanol was added at 
0 oC carefully. The reaction mixture was stirred at room temperature for 2 h to acquire 
series a compound.
4.1.3. The procedure for synthesis of c9
  Compound c9 was obtained from a9. To a solution of a9 (138.4 mg, 1.0 equiv) in 
anhydrous CH2Cl2 (2 mL), DIPEA (276.8 μL, 3.5 equiv) was added at 0 oC carefully. 
After stirring for 5 minutes, pivaloyl chloride (83.9 μL, 1.5 equiv) was added dropwise 
and the reaction continued at room temperature for 2 h. The mixture was extracted with 
EtOAc and the organic phases were washed with brine, dried over Na2SO4 and finally 
purified with column chromatography (PE/EtOAc = 3:1) to obtain c9 as a white solid 
(43 mg, 27 % yield).
4.1.4. The procedures for synthesis of a10 and b10
  Compounds a10 and b10 were obtained from b9. To a solution of b9 (50 mg, 1.0 
equiv) in anhydrous THF at 0 oC was added NaH (8 mg, 1.5 equiv). The reaction 
mixture was stirred for 30 min, and then benzyl bromide (24 μL, 1.2 equiv) was added. 
The reaction mixture was then warmed to room temperature and stirred for 2 h. The 
mixture was extracted with EtOAc and the organic phases were washed with brine, 
dried over Na2SO4 and finally purified with column chromatography (PE/EtOAc = 8:1) 
to obtain b10 as a white solid (30 mg, 48 % yield). Compound b10 (25 mg, 1.0 equiv) 
was weighed into the bottle, and a HCl solution in methanol was added at 0 oC carefully. 
The reaction mixture was stirred at room temperature for 2 h to acquire a10 as a yellow 
solid (10 mg, 46 % yield) after the solvent was removed under a vacuum.
4-(2-Aminocyclopropyl)-N-ethylbenzenesulfonamide (a1).
Yellow solid, 91 % yield, 96 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.78 (d, 
J = 8.0 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 3.00-2.93 (m, 1H), 2.87 (q, J = 7.2 Hz, 2H), 
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2.51 (m, 1H), 1.59-1.49 (m, 1H), 1.43 (m, 1H), 1.04 (t, J = 7.2 Hz, 3H). 13C NMR (100 
MHz, methanol-d4) δ 145.1, 140.3, 128.4, 128.1, 39.0, 32.4, 22.4, 15.2, 14.5. HRMS 
(ESI): m/z calcd for C11H16N2O2S (M+H)+, 241.1005; found, 241.1000.
Tert-butyl (2-(4-(N-ethylsulfamoyl)phenyl)cyclopropyl)carbamate (b1).
White solid, 72 % yield, 99 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.72 (d, J 
= 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 2.86 (q, J = 7.3 Hz, 2H), 2.72 (m, 1H), 2.10-
2.02 (m, 1H), 1.43 (s, 9H), 1.25 (t, J = 7.0 Hz, 2H), 1.04 (t, J = 7.3 Hz, 3H). 13C NMR 
(100 MHz, methanol-d4) δ 159.0, 148.2, 139.1, 128.0, 127.6, 39.0, 34.6, 28.7, 25.7, 17.1, 
15.2. HRMS (ESI): m/z calcd for C16H24N2O4S (M-H)-, 339.1384; found, 339.1377.
4-(2-Aminocyclopropyl)-N-phenethylbenzenesulfonamide (a2).
Yellow solid, 92 % yield, 98 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.70 (d, 
J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 7.18 (m, 2H), 7.11 (m, 1H), 7.06 (d, J = 6.9 
Hz, 2H), 3.03-2.96 (m, 2H), 2.95-2.89 (m, 1H), 2.70-2.63 (m, 2H), 2.52 (m, 1H), 1.58-
1.50 (m, 1H), 1.41-1.32 (m, 1H). 13C NMR (100 MHz, methanol-d4) δ 145.1, 140.3, 
139.9, 129.7, 129.5, 128.3, 128.1, 127.4, 45.6, 37.1, 32.4, 22.4, 14.5. HRMS (ESI): m/z 
calcd for C17H20N2O2S (M+H)+, 317.1318; found, 317.1333.
Tert-butyl (2-(4-(N-phenethylsulfamoyl)phenyl)cyclopropyl)carbamate (b2).
White solid, 64 % yield, 100 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.70 (d, 
J = 8.4 Hz, 2H), 7.22-7.28 (m, 4H), 7.17 (d, J = 7.2 Hz, 1H), 7.10 (d, J = 7.0 Hz, 2H), 
3.04 (t, J = 7.5 Hz, 2H), 2.75-2.67 (m, 3H), 2.09-2.00 (m, 1H), 1.43 (s, 9H), 1.31-1.21 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ 156.4, 146.5, 137.8, 137.3, 128.9, 127.3, 127.0, 
126.9, 80.0, 44.3, 35.9, 28.5, 17.0. HRMS (ESI): m/z calcd for C22H28N2O4S (M-H)-, 
415.1697; found, 415.1689.
4-(2-Aminocyclopropyl)-N-cyclohexylbenzenesulfonamide (a3).
Pale yellow solid, 76 % yield, 99 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.80 
(d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 2.97 (m, 1H), 2.50 (m, 1H), 1.65 (m, 4H), 
1.57-1.50 (m, 2H), 1.44 (m, 1H), 1.24-1.05 (m, 6H). 13C NMR (100 MHz, methanol-
d4) δ 144.9, 141.9, 128.2, 128.0, 53.9, 34.9, 32.5, 26.3, 26.0, 22.4, 14.6. HRMS (ESI): 
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m/z calcd for C15H22N2O2S (M+H)+, 295.1475; found, 295.1483.
Tert-butyl (2-(4-(N-cyclohexylsulfamoyl)phenyl)cyclopropyl)carbamate (b3).
White solid, 62 % yield, 100 % purity. 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 
8.3 Hz, 2H), 7.21 (d, J = 7.7 Hz, 2H), 4.94 (s, 1H), 4.68 (d, J = 7.5 Hz, 1H), 3.15-3.03 
(m, 1H), 2.77 (m, 1H), 2.09 (m, 1H), 1.66-1.57 (m, 2H), 1.54-1.46 (m, 2H), 1.43 (s, 
9H), 1.28-1.06 (m, 8H). 13C NMR (100 MHz, CDCl3) δ 146.2, 138.9, 127.1, 127.0, 80.0, 
52.7, 34.0, 29.8, 28.5, 25.3, 24.7, 17.0. HRMS (ESI): m/z calcd for C20H30N2O4S 
(M+H)+, 395.1999; found, 395.1984.
4-(2-Aminocyclopropyl)-N-(tert-butyl)benzenesulfonamide (a4).
Yellow solid, 97 % yield, 96 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.81 (d, 
J = 8.2 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 3.31 (s, 1H), 2.99-2.91 (m, 1H), 2.48 (m, 1H), 
1.58-1.47 (m, 1H), 1.43 (m, 1H), 1.16 (s, 9H). 13C NMR (100 MHz, methanol-d4) δ 
144.7, 144.0, 128.2, 127.8, 54.8, 32.4, 30.4, 22.4, 14.6. HRMS (ESI): m/z calcd for 
C13H20N2O2S (M+H)+, 269.1318; found, 269.1310.
Tert-butyl (2-(4-(N-(tert-butyl)sulfamoyl)phenyl)cyclopropyl)carbamate (b4).
White solid, 44 % yield, 99 % purity. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.4 
Hz, 2H), 7.19 (d, J = 8.1 Hz, 2H), 4.98 (s, 1H), 4.90 (s, 1H), 2.75 (m, 1H), 2.07 (m, 
1H), 1.43 (s, 9H), 1.23 (m, 1H), 1.20 (m, 1H), 1.19 (s, 9H). 13C NMR (100 MHz, CDCl3) 
δ 156.5, 145.9, 141.1, 127.1, 126.8, 80.0, 54.7, 33.3, 30.2, 28.5, 25.4, 16.9. HRMS (ESI): 
m/z calcd for C18H28N2O4S (M-H)-, 367.1697; found, 367.1684. 
4-(2-Aminocyclopropyl)-N-phenylbenzenesulfonamide (a5).
White solid, 82 % yield, 96 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.69 (d, J 
= 7.8 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 7.19 (t, J = 7.6 Hz, 2H), 7.09-7.01 (m, 3H), 
2.94-2.87 (m, 1H), 2.46-2.38 (m, 1H), 1.52-1.45 (m, 1H), 1.39 (d, J = 6.9 Hz, 1H). 13C 
NMR (100 MHz, methanol-d4) δ 145.5, 139.4, 138.9, 130.1, 128.6, 127.9, 125.7, 122.2, 




White solid, 26 % yield, 99 % purity. 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.2 
Hz, 2H), 7.22 (d, J = 7.7 Hz, 2H), 7.13 (m, 3H), 7.05 (d, J = 7.9 Hz, 2H), 6.73 (s, 1H), 
4.86 (s, 1H), 2.73 (m, 1H), 2.04 (m, 1H), 1.42 (s, 9H), 1.24 – 1.16 (m, 2H). 13C NMR 
(100 MHz, methanol-d4) δ 159.0, 148.6, 139.0, 138.2, 130.1, 128.2, 127.4, 125.7, 122.2, 
80.4, 34.6, 28.7, 25.7, 17.1. HRMS (ESI): m/z calcd for C20H24N2O4S (M+H)+, 
389.1530; found, 389.1531.
4-(2-Aminocyclopropyl)-N-(pyridin-2-yl)benzenesulfonamide (a6).
Yellow solid, 89 % yield, 95 % purity. 1H NMR (400 MHz, methanol-d4) δ 8.25 (d, 
J = 5.7 Hz, 1H), 8.13 (t, J = 7.9 Hz, 1H), 7.88 (d, J = 8.1 Hz, 2H), 7.45-7.30 (m, 4H), 
2.92 (m, 1H), 2.49 (m, 1H), 1.56-1.49 (m, 1H), 1.38 (dd, J = 14.0, 6.8 Hz, 1H). 13C 
NMR (100 MHz, methanol-d4) δ 150.3, 146.9, 141.7, 139.2, 128.5, 120.2, 117.6, 101.3, 
32.5, 22.4, 14.7. HRMS (ESI): m/z calcd for C14H15N3O2S (M+H)+, 290.0958; found, 
290.0958.
Tert-butyl (2-(4-(N-(pyridin-2-yl)sulfamoyl)phenyl)cyclopropyl)carbamate (b6).
Yellow solid, 50 % yield, 99 % purity. 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 
5.9 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.64 (t, J = 7.3 Hz, 1H), 7.37 (d, J = 8.9 Hz, 1H), 
7.17 (d, J = 7.9 Hz, 2H), 6.78 (t, J = 6.4 Hz, 1H), 4.89 (s, 1H), 2.72 (m, 1H), 2.05 (m, 
1H), 1.42 (s, 9H), 1.27-1.15 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 155.4, 145.8, 
142.5, 140.2, 139.4, 127.0, 126.9, 115.4, 113.9, 33.1, 28.5, 25.3, 16.9. HRMS (ESI): 
m/z calcd for C19H23N3O4S (M+H)+, 390.1482; found, 390.1468.
2-(4-(Morpholinosulfonyl)phenyl)cyclopropan-1-amine (a7).
Pale yellow solid, 91 % yield, 95 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.72 
(d, J = 7.9 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 3.72-3.66 (m, 4H), 2.99 (m, 1H), 2.96-
2.91 (m, 4H), 2.55-2.47 (m, 1H), 1.59-1.50 (m, 1H), 1.46 (dd, J = 13.8, 6.9 Hz, 2H). 
13C NMR (100 MHz, methanol-d4) δ 146.0, 142.6, 129.4, 128.3, 67.2, 47.4, 32.5, 22.4, 
14.7. HRMS (ESI): m/z calcd for C13H18N2O3S (M+H)+, 283.1111; found, 283.1104.
Tert-butyl (2-(4-(morpholinosulfonyl)phenyl)cyclopropyl)carbamate (b7).
Yellow solid, 37 % yield, 97 % purity. 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 
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7.9 Hz, 2H), 7.27 (d, J = 7.8 Hz, 2H), 4.92 (s, 1H), 3.76-3.68 (m, 4H), 2.99-2.91 (m, 
4H), 2.77 (m, 1H), 2.11 (m, 1H), 1.44 (s, 9H), 1.25 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 156.3, 147.0, 132.6, 128.1, 127.1, 66.2, 46.1, 28.5, 17.0. HRMS (ESI): m/z 
calcd for C18H26N2O5S (M+H)+, 383.1635; found, 383.1621.
2-(4-(Pyrrolidin-1-ylsulfonyl)phenyl)cyclopropan-1-amine (a8).
Yellow solid, 94 % yield, 97 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.72 (d, 
J = 8.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 3.16 (t, J = 6.7 Hz, 4H), 2.98-2.91 (m, 1H), 
2.51 (m, 1H), 1.73-1.64 (m, 4H), 1.58-1.50 (m, 1H), 1.40 (m, 1H). 13C NMR (100 MHz, 
methanol-d4) δ 145.6, 136.6, 129.0, 128.2, 32.5, 26.2, 22.4, 14.6. HRMS (ESI): m/z 
calcd for C13H18N2O2S (M+H)+, 267.1162; found, 267.1156.
Tert-butyl (2-(4-(pyrrolidin-1-ylsulfonyl)phenyl)cyclopropyl)carbamate (b8).
White solid, 57 % yield, 99 % purity. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.3 
Hz, 1H), 7.24 (d, J = 8.2 Hz, 1H), 3.21 (t, J = 6.7 Hz, 2H), 2.76 (m, 1H), 2.14-2.05 (m, 
1H), 1.78-1.71 (m, 4H), 1.44 (s, 9H), 1.27-1.20 (m, 2H). 13C NMR (100 MHz, CDCl3) 
δ 156.5, 146.4, 134.5, 127.8, 126.9, 80.0, 48.0, 28.5, 25.3, 16.9. HRMS (ESI): m/z calcd 
for C18H26N2O4S (M+H)+, 367.1686; found, 367.1678.
4-(2-Aminocyclopropyl)-N,N-diethylbenzenesulfonamide (a9).
Yellow solid, 58 % yield, 99 % purity. 1H NMR (400 MHz, methanol-d4) δ 7.71 (d, 
J = 8.0 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 3.18 (q, J = 7.1 Hz, 4H), 2.95-2.88 (m, 1H), 
2.48 (m, 1H), 1.56-1.47 (m, 1H), 1.39 (m, 1H), 1.07 (t, J = 7.1 Hz, 6H). 13C NMR (100 
MHz, CDCl3) δ 143.5, 138.9, 127.8, 127.6, 42.5, 14.5, 14.2. HRMS (ESI): m/z calcd 
for C13H20N2O2S (M+H)+, 269.1318; found, 269.1310.
Tert-butyl (2-(4-(N,N-diethylsulfamoyl)phenyl)cyclopropyl)carbamate (b9).
White solid, 47 % yield, 99 % purity. 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.4 
Hz, 2H), 7.21 (d, J = 8.2 Hz, 2H), 3.20 (q, J = 7.1 Hz, 4H), 2.75 (m, 1H), 2.13-2.03 (m, 
1H), 1.44 (s, 9H), 1.26-1.18 (m, 2H), 1.12 (t, J = 7.1 Hz, 6H). 13C NMR (100 MHz, 
CDCl3) δ 156.3, 146 .0, 137.8, 127.2, 126.9, 80.0, 42.2, 33.2, 28.5, 25.3, 16.9, 14.4. 
HRMS (ESI): m/z calcd for C18H28N2O4S (M+H)+, 369.1843; found, 369.1846.
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N-(2-(4-(N,N-diethylsulfamoyl)phenyl)cyclopropyl)pivalamide (c9).
White solid, 27 % yield, 95 % purity. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 8.3 
Hz, 2H), 7.28 (d, J = 8.3 Hz, 2H), 5.90 (s, 1H), 3.20 (q, J = 7.1 Hz, 4H), 2.88 (m, 1H), 
2.05 (m, 1H), 1.29 (m, 2H), 1.20 (s, 9H), 1.12 (t, J = 7.1 Hz, 6H). 13C NMR (100 MHz, 
CDCl3) δ 180.0, 145.8, 137.9, 127.2, 127.2, 42.2, 38.7, 32.9, 27.6, 25.2, 16.4, 14.3. 
HRMS (ESI): m/z calcd for C18H28N2O3S (M+H)+, 353.1893; found, 353.1885.
4-(2-(Benzylamino)cyclopropyl)-N,N-diethylbenzenesulfonamide (a10).
Yellow solid, 46 % yield, 97 % purity. 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 
7.8 Hz, 2H), 7.53 (s, 2H), 7.34 (m, 3H), 7.04 (d, J = 7.9 Hz, 2H), 4.12 (m, 2H), 3.20 (q, 
J = 7.1 Hz, 4H), 2.75 (m, 1H), 2.55 (m, 1H), 1.25 (m, 2H), 1.11 (t, J = 7.1 Hz, 6H). 13C 
NMR (125 MHz, CDCl3) δ 142.9, 139.1, 131.6, 130.0, 129.8, 129.6, 128.0, 127.7, 53.6, 
42.5, 29.8, 14.5. HRMS (ESI): m/z calcd for C20H26N2O2S (M+H)+, 359.1788; found, 
359.1777.
Tert-butyl benzyl(2-(4-(N,N-diethylsulfamoyl)phenyl)cyclopropyl)carbamate (b10).
White solid, 48 % yield, 96 % purity. 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.3 
Hz, 2H), 7.33-7.28 (m, 2H), 7.23 (t, J = 6.5 Hz, 3H), 7.16-7.09 (m, 2H), 4.62 (d, J = 
15.2 Hz, 1H), 4.35 (d, J = 15.4 Hz, 1H), 3.20 (q, J = 7.1 Hz, 4H), 2.73-2.66 (m, 1H), 
2.18 (m, 1H), 1.41 (s, 9H), 1.20 (m, 2H), 1.10 (t, J = 7.2 Hz, 6H). 13C NMR (125 MHz, 
CDCl3) δ 146.2, 138.6, 137.8, 130.6, 128.7, 127.6, 127.3, 127.1, 126.7, 80.4, 42.1, 39.6, 




AML cell lines MV4-11, HL-60, THP-1, U937, ML1, MOLM-13 and BaF3/ITD 
were obtained from American Type Culture Collection (Rockville, MD, USA) and 
maintained in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10 
% fetal bovine serum (FBS, Biological Industries, Israel). Kasumi-1 cell line was kindly 
provided by Stem Cell Bank, Chinese Academy of Sciences and cultured in RPMI 1640 
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medium containing 20 % FBS, 1 % GlutaMAX™-I (Gibco, Carlsbad, CA, USA) and 1 
% sodium pyruvate (Gibco, Carlsbad, CA, USA). All cell lines were incubated at 37 oC 
supplied with 5 % carbon dioxide.
4.2.2. Cell proliferation assays through MTS and cell counting
Cell viability was determined by MTS assay. MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) can be 
reduced by dehydrogenase enzymes in metabolically active cells into a colored 
formazan product that is soluble in the medium and is directly detected by visible light 
absorption at 490 nm with a 96-well plate reader. Briefly, cells were plated at 5000 cells 
per well in round bottom 96-well plates in triplicate. After 2 h of incubation at the 37 
oC incubator, the cells were exposed to gradient concentrations of typical LSD1 
inhibitors or our synthetic compounds for 6 days. At the end of the incubation, 20 μL 
of MTS solution (2 mg/mL) was added into each well and the cells were incubated at 
37 oC supplied with 5 % carbon dioxide for 4 h. Then the optical density value (OD) 
was determined at 490 nm wavelength with a BioTek Gen5 microplate-reader (BioTek 
Instruments, Winooski, Vermont, USA).
To directly quantify the cell proliferation, cell numbers were counted using a cell 
counter (Cellometer Auto T4, Nexcelom Bioscience, Lawrence, MA, USA). Briefly, 
cells were plated at 1 × 105 cells per well in 6-well plates. After 2 h of incubation, the 
cells were subjected to three typical LSD1 inhibitors (TCP, ORY-1001 and 
GSK2879552) at 5 μM for 8 days. On the last day, the cells were resuspended 
thoroughly and counted via the cell counter.
4.2.3. LSD1 enzymatic inhibition measurement
Enzymatic inhibition rate was measured by a commercially available LSD1 Inhibitor 
Screening Assay Kit (#700120, Cayman Chemical, USA) according to the 
manufacturer’s instructions. In brief, the reagents including diluted assay buffer, LSD1 
protein, horseradish peroxidase and fluorometric substrate were added into the plates 
successively. Then gradient concentrations of our synthetic compounds were added. 
Finally, the reaction was initiated by the addition of the peptide corresponding to the 
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first 21 amino acids of N-terminal tail of histone H3 with a di-methylated lysine at 
residue 4. The plate was covered and incubated at 37 oC for 30 minutes. At the end of 
the incubation, the plate was read using an excitation wavelength of 530-540 nm and 
an emission wavelength of 585-595 nm. The enzymatic inhibition rates were calculated 
by dividing the control group after deduction of the background effect.
4.2.4. Cellular thermal shift assay
Exponential growth phase MV4-11 cells (1 × 106 cells/well) were seeded in a 6-well 
plate and incubated with compounds either a9, b9, c9 or a10 at 5 μM for 24 h in the 5 
% CO2 containing incubator at 37 oC. Then, the cells were centrifuged at 1000 rpm for 
3 min, washed three times with PBS, resuspended with 1 mL PBS containing 1 % 
protease inhibitors, and divided equally into eight PCR tubes (100 μL cell solution per 
tube). The tubes were treated with gradient temperatures (40 oC-58 oC) for 3 minutes in 
a PCR thermal cycler, placed at room temperature for 3 minutes and then subjected to 
snap-freezing in liquid nitrogen for 3 minutes. The above cycles were repeated three 
times. The thawed cell lysates were centrifuged at 20000 g at 4 oC for 20 minutes, and 
then the supernatants were collected carefully for further Western Blot analysis.
4.2.5. Detection of a9 in cell samples via LC-MS/MS
The cells were seeded in a 6-well plate and incubated with compounds either a9, b9 
or c9 at 10 μM for 3 days and 6 days, respectively. At the end of the incubation, the 
cells were washed twice with cold saline, lysed and extracted using the solution 
(chloroform : methanol : water = 6 : 3 : 1). The extract was dried via nitrogen blower 
concentrator and then re-dissolved in 100 μL of 50 % MeOH/H2O solution for LC-
MS/MS detection.
Chromatographic separation was performed using an Agilent 1290 Infinity II liquid 
chromatography system (Agilent, USA) with ZORBAX Eclipse Plus C18 analytical 
column (2.1×50 mm, 1.8 µm particle size) (Waters, USA). The flow rate of HPLC was 
set at 0.4 mL/min and the gradient elution was run for 15 min, from 10 % MeOH/H2O 
to 90 % MeOH/H2O for 10 min and 90 % MeOH/H2O for another 5 min. The 6495 
Triple Quad mass spectrometer (Agilent, USA) with an electrospray ionization (ESI) 
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interface operated in positive mode was used for the multiple reaction monitoring 
(MRM) LC-MS/MS analysis. The following precursor and product ion transitions were 
used for MRM: a9, 269.1→115.1, 269.1→162.2. MS data were processed using the 
Agilent MassHunter Quantitative Analysis (Version B.07.00, Agilent, USA).
4.2.6. Flow cytometric analysis of cell differentiation and cell cycle
Cell differentiation was determined by flow cytometry using anti-CD11b (#553311, 
BD biosciences, New Jersey, USA). In brief, cells were seeded in the 24-well plate and 
incubated with different compounds at 10 μM for 24 h and 96 h. At the end of the 
incubation, the cells were centrifuged at 800 rpm for 5 minutes to remove dead cells, 
washed twice with 1 mL cold PBS and then incubated with a solution containing CD11b 
antibody at 4 oC for 30 minutes. Then, the cells were washed and resuspended with 300 
μL cold PBS for final detection by flow cytometer.
Cell cycle was detected by staining DNA with PI/RNase solution (#550825, BD 
biosciences, New Jersey, USA) using flow cytometry. Briefly, the cells (1×105 for 24 
h and 4×105 for 96 h treatment) were seeded in the 24-well plate and incubated with 
either TCP, ORY-1001, GSK2879552 or a10 at 10 μM for 24 h and 96 h. At the end of 
the incubation, the cells were centrifuged at 1000 rpm for 3 min, washed once with 1 
mL cold PBS and then resuspended with 500 μL of 70 % MeOH/H2O solution for 4 h. 
After removal of methanol through centrifugation at 1000 rpm for 3 min, the cells were 
incubated with 300 μL PI/RNase solution, for 30 minutes at room temperature. At the 
end of the incubation, the resuspended cell solution was directly tested by flow 
cytometry.
4.2.7. MAO-A and MAO-B enzymatic inhibition assay
The measurement of MAO-A and MAO-B enzymatic inhibition rates was conducted 
by the company (Jiangsu Meimian industrial Co., Ltd). In brief, recombinant MAO-A 
protein (240 μL), inhibitors (360 μL) and 100 mM potassium phosphate solution (100 
μL) were added into the tubes sequentially and incubated at 37 oC for 20 min. At the 
end of the incubation, 10 g/L 5-hydroxytryptamine (100 μL) was added and incubated 
at 37 oC for 60 min. Then the reaction was stopped with 60 % HClO4 (200 μL). The 
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reaction product (5- hydroxyindole-3-acetaldehyde) was extracted using butyl acetate 
(3 mL), centrifuged at 10000 g for 5 min, and the OD value was finally determined at 
280 nm wavelength. Similarly, recombinant MAO-B protein (190 μL), inhibitors (460 
μL) and 100 mM potassium phosphate solution (50 μL) were added into the tubes 
sequentially and incubated at 37 oC for 20 min. At the end of the incubation, 98.1 g/L 
benzylamine (100 μL) was added and incubated at 37 oC for 60 min. Then the reaction 
was stopped with 60 % HClO4 (200 μL). The reaction product (benzaldehyde) was 
extracted using cyclohexane (3 mL), centrifuged at 10000 g for 5 min, and the OD value 
was finally determined at 242 nm wavelength.
4.2.8. Western Blot
The MV4-11 cells (1 × 106 cells/well) were seeded in a 6-well plate and incubated 
with compound a9 at 1, 5, or 10 μM for 24 h in the 5 % CO2 containing incubator at 37 
oC. At the end of the incubation, the cells were centrifuged at 1000 rpm for 3 min, 
washed with PBS twice. Proteins from the collected cells were extracted in lysis buffer 
(5 % SDS, 10 mM EDTA, 250 mM NaCl, 10 mM Tris-HCl, pH 7.4), and were subjected 
to 95 oC heating for 15 min for thorough denaturation. The protein concentrations were 
measured via Pierce BCA protein assay (#23225, Thermo Fisher, Rockford, IL, USA). 
Each sample was adjusted to equal protein concentrations with relative quantification 
methods for Western Blot analysis. Briefly, the samples were subjected to 12 % SDS-
PAGE, and then transferred to PVDF membranes (Millipore, Billerica, MA, USA). 
After that, the proteins on the membranes were probed with primary antibodies and 
secondary antibodies, and then detected by ECL reagent (#34579, Thermo Fisher, 
Rockford, IL, USA). The antibodies used for Western Blot analysis, anti-H3 (#4499), 
anti-H3K4me1 (#5326), anti-H3K4me2 (#9725), anti-H3K9me2 (#4658) and anti-
LSD1 (#2139) were purchased from Cell Signaling Technology (Danvers, MA, USA).
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⚫ 21 novel compounds with para-sulfonamides based on TCP scaffolding were
synthesized to provide a potent LSD1 inhibitor with IC50 of 29 nM.
⚫ Boc was found to be a potential prodrug functional group which enhanced cellular
uptake of LSD1 inhibitors and improved their anti-proliferation activity.
⚫ Appropriate lipophilicity and potent LSD1 inhibition contributed to the improved
anti-proliferation effect towards acute myeloid leukemia of LSD1 inhibitors.
